Cumulus announced that it presented multiple studies at the International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference and the 38th European College of Neuropsychopharmacology (ECNP) Congress in Amsterdam.
According to the company, one poster showcased interim data from a Phase 1b trial with Delix Therapeutics evaluating DLX-001 (a novel neuroplastogen) in major depressive disorder using Cumulus’s NeuLogiq® platform to collect high-frequency neurophysiology and cognitive data. The poster reportedly highlighted evidence of target engagement and neuroplastic effects.
Another poster modelled data from Cumulus’s CNS-101 Alzheimer’s study, involving 59 patients with mild dementia and 60 age-matched controls monitored at home over 12 months. The company claims that repeated, brief digital cognitive assessments at home demonstrated greater sensitivity to change than the ADAS-Cog 13 benchmark, allowing for smaller cohorts in trials.
A third presentation modelled the trade-offs between reducing trial size versus shortening duration in Phase II trials for Alzheimer’s and depression. The analysis reportedly covered 77 Alzheimer’s and 55 depression trials, and suggested that cohort size reductions yielded greater time and cost savings in 81% of cases.
Cumulus positions these findings as evidence that digital endpoints can support more efficient, adaptive CNS trial designs, particularly when combined with combination in-clinic and remote monitoring tools.
